Pharmaceutical analyst Dr Martin Hall speaks to Proactive about an update to his research on ImmuPharma PLC (AIM:IMM, OTC:IMMPF), with whom he has worked closely.
ImmuPharma's lead program Lupuzor is an autophagy immunomodulator for the treatment of lupus. Hall discusses the potential for a further broadening of Immupharma's collaboration with its US partner Avion.